Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat + Exemestane in Chinese Postmenopausal Breast Cancer
NCT02833155Phase 1Completed
- Sponsor
- EOC Pharma
- Start
- Aug 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in breast cancer, sponsored by EOC Pharma. Primary endpoint: Adverse events, 12-lead ECG, blood pressure/pulse, temperature, laboratory parameters and physical examination up to 28 days. Started Aug 2016; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02833155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833155.